R. W. Williams

R. W. Williams's AcademicInfluence.com Rankings

R. W. Williams

Philosophy

#9056

World Rank

#12554

Historical Rank

Logic

#6056

World Rank

#7536

Historical Rank

philosophy Degrees

Download Badge

Philosophy

R. W. Williams's Degrees

Doctorate Medicine Harvard University

Why Is R. W. Williams Influential?

(Suggest an Edit or Addition)

(See a Problem?)

R. W. Williams's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Acute liver failure: redefining the syndromes (1993) (877)
Pilot‐controlled trial of the extracorporeal liver assist device in acute liver failure (1996) (516)
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. (1988) (515)
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. (1991) (510)
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. (1992) (336)
Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. (1982) (272)
Plasma and Brain Amino Acids in Fulminant Hepatic Failure and their Relationship to Hepatic Encephalopathy (1976) (270)
Wilson's disease: clinical presentation and use of prognostic index. (1986) (232)
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases (1998) (205)
Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. (1975) (186)
Classification, etiology, and considerations of outcome in acute liver failure. (1996) (169)
Maternal and perinatal outcome in severe pregnancy‐related liver disease (1997) (162)
Hepatic encephalopathy and cerebral edema. (1986) (161)
Tumour necrosis factor α is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis (2003) (156)
Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. (1986) (153)
Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. (1991) (141)
PLASMA AND BRAIN TRYPTOPHAN CHANGES IN EXPERIMENTAL ACUTE HEPATIC FAILURE (1973) (125)
Earlier identification of patients at risk from acetaminophen-induced acute liver failure. (1998) (123)
Cardiovascular, pulmonary and renal complications of fulminant hepatic failure. (1986) (121)
Tissue hypoxia during fulminant hepatic failure (1985) (116)
Remote ischaemic preconditioning of the hind limb reduces experimental liver warm ischaemia–reperfusion injury (2006) (112)
Lactic acidosis in fulminant hepatic failure. Some aspects of pathogenesis and prognosis. (1985) (107)
Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure (1994) (103)
Acid-base and metabolic disturbances in fulminant hepatic failure. (1975) (103)
Reticuloendothelial system and hepatocytic function in fulminant hepatic failure. (1982) (102)
Predicting survival in fulminant hepatic failure using serum Gc protein concentrations. (1995) (101)
Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. (1998) (100)
Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome. (1993) (100)
Coagulation factor V levels as a prognostic indicator in fulminant hepatic failure (1996) (97)
The safety and value of extradural intracranial pressure monitors in fulminant hepatic failure. (1993) (96)
Intravascular coagulation in acute hepatic necrosis. (1970) (94)
Clinical monitoring of intracranial pressure in fulminant hepatic failure. (1980) (89)
N-acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfunction. (1997) (86)
Early and intensive therapy of intravascular coagulation in acute liver failure. (1971) (86)
Metabolism of cysteinyl leukotrienes in monkey and man. (1990) (85)
Pathophysiology of hypotension in patients with fulminant hepatic failure. (1977) (81)
Fulminant hepatic failure in childhood (1980) (81)
PROSPECTS FOR EXTRACORPOREAL LIVER SUPPORT (2004) (81)
Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. (2004) (80)
Anti-tuberculous therapy and acute liver failure (1995) (77)
Fulminant hepatic failure secondary to hydroxychloroquine. (1994) (76)
Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure (1996) (73)
High resolution proton nuclear magnetic resonance studies of human cerebrospinal fluid. (1987) (69)
Bacteraemia in patients with fulminant hepatic failure. (2008) (68)
Use of bioartificial and artificial liver support devices. (1996) (66)
Metabolic profiling of body fluids by proton NMR: Self‐poisoning episodes with paracetamol (acetaminophen) (1988) (66)
Increased production of cysteinyl leukotrienes in hepatorenal syndrome. (1990) (60)
Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal haemoperfusion, and polyacrylonitrile haemodialysis. (1978) (59)
Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. (1991) (58)
The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. (1976) (56)
Frequency of arrhythmias and other cardiac abnormalities in fulminant hepatic failure. (1976) (54)
Extent of the acute phase response in fulminant hepatic failure. (1994) (53)
Regional cerebral edema and chloride space in galactosamine‐induced liver failure in rats (1997) (53)
Review article: the Molecular Adsorbents Recirculating System (MARS) in liver failure (2002) (52)
Effect of prostacyclin (PGI2) and a prostaglandin analogue BW 245C on galactosamine-induced hepatic necrosis. (1986) (50)
Temporary Extracorporeal Liver Support for Severe Acute Alcoholic Hepatitis Using the Biologic-DT (1999) (50)
Temporary Extracorporeal Liver Support for Severe Acute Alcoholic Hepatitis Using the Biologic-Dt (1998) (49)
Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. (1998) (48)
Effects of Serial Resin Hemoperfusion in Fulminant Hepatic Failure (1983) (47)
A prospective reappraisal of emergency endoscopy in patients with portal hypertension. (1982) (45)
The inflammatory basis of intracranial hypertension in acute liver failure. (2001) (45)
Frequency of pancreatitis in fulminant hepatic failure using isoenzyme markers. (1988) (44)
Fibronectin in fulminant hepatic failure. (1982) (44)
Serum, cerebrospinal fluid, and brain levels of bile acids in patients with fulminant hepatic failure. (1977) (41)
Albumin-coated Amberlite XAD-7 resin for hemoperfusion in acute liver failure. Part II: in vivo evaluation. (1979) (40)
Factors contributing to mortality in paracetamol-induced hepatic failure. (1981) (38)
Neutrophil adherence in chronic liver disease and fulminant hepatic failure. (1983) (37)
Prognostic value of serum alpha-fetoprotein in fulminant hepatic failure including patients treated by charcoal haemoperfusion. (1976) (37)
Failure of insulin and glucagon infusion to stimulate liver regeneration in fulminant hepatic failure. (1990) (36)
Liver Transplantation in Man—IV, Haemorrhage and Thrombosis (1969) (35)
Albumin-coated Amberlite XAD-7 resin for hemoperfusion in acute liver failure. Part I: adsorption studies. (1979) (35)
Spontaneous bacterial peritonitis. (1985) (35)
In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines. (1992) (34)
The relationship between plasma and brain quinolinic acid levels and the severity of hepatic encephalopathy. (1995) (33)
Systemic and hepatic hemodynamic changes in acute liver injury. (1997) (33)
Coagulation abnormalities in acute liver failure; pathogenetic and therapeutic implications. (1973) (32)
A dog model of fulminant hepatic failure produced by paracetamol administration. (1975) (32)
Glutathione S-transferase levels in autoimmune chronic active hepatitis: a more sensitive index of hepatocellular damage than aspartate transaminase. (1988) (32)
Biochemical mechanisms of hepatic encephalopathy. (1983) (31)
Plasma hepatocyte growth factor and biliprotein levels and outcome in fulminant hepatic failure. (1994) (31)
A model to study total hepatic ischemia-reperfusion injury. (2004) (30)
Controlled trial of antithrombin III supplementation in fulminant hepatic failure. (1993) (30)
Plasma short-chain fatty acids in fulminant hepatic failure. (1977) (29)
Neurological sequelae in patients recovered from fulminant hepatic failure. (1987) (29)
Prospective comparison of two Sengstaken tubes in the management of patients with variceal haemorrhage. (1980) (29)
Disorderd hemostasis in liver damage from paracetamol overdose. (1973) (29)
Progress in the treatment of chronic portasystemic encephalopathy. (1984) (28)
Fulminant hepatic failure. (2000) (28)
Rapid inhibition of DNA synthesis in hepatocytes from regenerating rat liver by serum from patients with fulminant hepatic failure. (1982) (28)
75Se-selenomethionine in the scintiscan diagnosis of primary hepatocellular carcinoma (1971) (27)
Budd-Chiari syndrome presenting as fulminant hepatic failure. (1986) (27)
Use of sorbent columns and haemofiltration in fulminant hepatic failure. (1993) (27)
Late-onset hepatic failure: clinical features, serology and outcome following transplantation. (1995) (27)
Platelet adhesiveness to glass beads in liver disease. (1982) (26)
Metal ions catalytic for free radical reactions in the plasma of patients with fulminant hepatic failure. (1994) (25)
Induction and role of NO synthase in hypotensive hepatic failure. (1997) (25)
Intravascular coagulation in acute hepatic necrosis. (1970) (25)
Effects of cerebral oedema and arterial hypotension on cerebral blood flow in an animal model of hepatic failure (1978) (24)
Renal function in fulminant hepatic failure: haemodynamics and renal prostaglandins. (1987) (24)
Subacute hepatic necrosis induced by piroxicam. (1986) (24)
Circulating lysosomal enzymes and acute hepatic necrosis. (1981) (24)
Hepatotoxicity of antituberculosis drugs. (1996) (24)
Natural history of acute decompensation of cirrhosis: The basis of the definition, prognosis and pathophysiology of acute on chronic liver failure (2006) (24)
Potential toxins of acute liver failure and their effects on blood-brain barrier permeability (1983) (23)
Experimental hepatic necrosis: Studies on coagulation abnormalities, plasma clearance, and organ distribution of 125I-labelled fibrinogen (1973) (23)
Reduced brain Na+, K+-ATPase activity in rats with galactosamine-induced hepatic failure: relationship to encephalopathy and cerebral oedema. (1987) (22)
Effect of ELAD Liver Support on Plasma HGF and TGF–β1 in Acute Liver Failure (1996) (22)
Acquired Dysfibrinogenemia in Acute and Chronic Liver Disease (1977) (21)
Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation. (1998) (21)
Synthesis and metabolism of cysteinyl leukotrienes by the isolated pig kidney. (1992) (21)
Fibrinogen derivatives and platelet activation products in acute and chronic liver disease. (1985) (20)
Determination of the ketone body ratio in fulminant hepatic failure. (1990) (19)
Effects of converting enzyme inhibitor on hepatic blood flow in man. (1984) (19)
Inhibition of partially purified rat brain Na+, K+-dependent ATPase by bile acids, phenolic acids and endotoxin. (1984) (19)
Assessment of Bioartificial Liver Support in Acute Liver Failure (1996) (18)
Artificial liver support in acute liver failure: a review of studies at King's. (2008) (18)
Polymorph leucocyte function in uraemia and jaundice. (1980) (17)
Management of liver failure. (1986) (17)
Plasma inhibitory activity against tumour necrosis factor in fulminant hepatic failure. (1996) (17)
Adsorption of human serum albumin to Amberlite XAD-7 resin. (1979) (16)
Primary sepsis presenting as fulminant hepatic failure. (1989) (15)
The use of prostacyclin, PGI2, in the prevention of platelet aggregation during charcoal haemoperfusion. (1979) (15)
Physiological inhibitors of coagulation in fulminant hepatic failure (1992) (15)
Evaluation of extracorporeal bioartificial liver devices. (1995) (14)
Anoxic hepatic and intestinal injury from carbon monoxide poisoning. (1984) (14)
Depressed uptake of serotonin by platelets in hepatic encephalopathy. (1980) (14)
Increased elastase-alpha 1-antitrypsin complex in fulminant hepatic failure: relationship to bacterial infection and activation of coagulation. (1991) (13)
Plasma levels and hepatic mRNA expression of transforming growth factor-beta1 in patients with fulminant hepatic failure. (1997) (13)
Protective effects of propylene glycol, a solvent used pharmaceutically, against paracetamol-induced liver injury in mice. (1991) (12)
The diagnosis of primary malignant tumours of the liver. Findings in 48 consecutive patients. (1972) (12)
Removal of inhibitors of brain Na+, K+-ATPase by hemoperfusion in fulminant hepatic failure. (1984) (11)
Myocarditis and fulminant hepatic failure from coxsackievirus B infection. (1985) (11)
Plasma amino acids in experimental acute hepatic failure and their relationship to brain tryptophan. (1974) (11)
Prognostic value of the oculovestibular reflex in fulminant hepatic failure. (1978) (11)
The use of an in vitro haemoperfusion circuit to evaluate the blood compatibility of albumin-coated Amberlite XAD-7 resin. (1978) (10)
Liver scintiscanning in acute hepatic necrosis. (1971) (10)
In-Vitro Blood Compatibility Studies on a New Polymer-Coated Charcoal for Haemoperfusion (1980) (10)
Glycerol therapy for cerebral oedema complicating fulminant hepatic failure. (1975) (9)
Antithrombin III Infusion During Fulminant Hepatic Failure (1981) (9)
Wilson's disease: a diagnostic dilemma. (1983) (9)
Clearance and tissue distribution of staphylococcal enterotoxin A in the rat and potential use of adsorbents for removal from plasma. (1993) (9)
Treatment of fulminant hepatic failure. Clinical syndrome and basis of therapy. (1971) (9)
Synthesis and metabolism of cysteinyl leukotrienes by the isolated pig kidney. (1992) (8)
In vivo and in vitro studies on the protective effects of 9 beta-methylcarbacyclin, a stable prostacyclin analogue, in galactosamine-induced hepatocellular damage. (1990) (8)
Thermal desorption-gas chromatography of plasma isovaleraldehyde in hepatic encephalopathy in man. (1987) (8)
Continuous bipolar recording of the EEG in patients with fulminant hepatic failure. (1978) (8)
Effect of supernatants from Kupffer cells stimulated with galactosamine and endotoxin on the function of isolated rat hepatocytes. (1993) (7)
Metabolic effects of beta-adrenergic receptor blockade in advanced alcoholic cirrhosis. (1993) (7)
Fibrinolytic abnormalities following liver transplantation in patients with fulminant hepatic failure. (1995) (7)
Neutrophil Adherence during Hemoperfusion in Fulminant Hepatic Failure (1982) (7)
Artificial liver support: Overview of Registry and controlled clinical trials (2003) (7)
Sodium handling in the isolated perfused kidney of the cirrhotic rat. (1989) (7)
Affinity chromatography systems for artificial liver support. (1977) (7)
Platelet function during haemoperfusion in acute liver failure (1980) (6)
Progress in the management of fulminant hepatic failure (1981) (6)
Raised serum biliverdin in hepatic necrosis. (1981) (6)
MARS: a new treatment for hepatorenal failure. Molecular adsorbent and recirculating system. (2000) (6)
FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure (1994) (6)
Physico-chemical aspects of the removal of protein-bound substances by charcoal and other adsorbents of potential value in systems of artificial liver support: Part 1—Equilibrium properties (1978) (6)
Mars in decompensated alcoholic liver disease with multi-organ failure. (2001) (6)
Artificial liver support in fulminant hepatic failure. (1975) (5)
The effect of prostaglandin E1 and adenosine on adverse platelet reactions during charcoal haemoperfusion. (1978) (5)
TREATMENT WITH INFLIXIMAB INCREASES E-NOS ACTIVITY IN CIRRHOSIS THROUGH MODULATION OF THE DDAH-ADMA PATHWAY (2009) (5)
A circulating inhibitor of leucocyte sodium transport in patients with advanced liver cirrhosis. (1984) (5)
Physico-chemical aspects of the removal of protein-bound substances by charcoal and other adsorbents of potential value in systems of artificial liver support: Part 2—Kinetics of removal (1978) (4)
Proceedings: Defective platelet function with deficiency of 'sticky platelets' in fulminant hepatic failure. (1975) (4)
Liver disease in childhood: principles of management. (1974) (4)
Pulmonary complications in fulminant hepatic failure: analysis of serial radiographs from 100 consecutive patients. (1978) (4)
A Review of Mediators and the Hepatorenal Syndrome (1990) (3)
Protein synthesis by the liver after transplantation. (1970) (3)
Intravascular coagulation in acute hepatic necrosis: clinical and experimental studies into the deposition of microthrombi and the effect of treatment. (1971) (3)
Studies on plasma cytotoxicity and liver regeneration in fulminant hepatic failure. (1977) (3)
Intravascular coagulation in acute hepatic failure. (1970) (3)
Splanchnic ischemia is associated with increased intestinal permeability, endotoxemia and bacteremia in general intensive care patients but not in acute liver failure (1998) (3)
Use of artificial liver support. (1985) (3)
Plasma prostaglandins in fulminant hepatic failure. (1975) (3)
Use of prostacyclin in extracorporeal circulation. (1985) (3)
Diagnosis and prognosis of primary malignant tumors of the liver. (1970) (3)
Histological appearances in fulminant hepatic failure with reference to aetiology, time of survival and role of immunological processes. (1973) (3)
Hepatocyte growth factor and plasminogen activation in fulminant hepatic failure. (1994) (3)
TREATMENT OF ACETAMINOPHEN-INDUCED HEPATITIS AND FULMINANT HEPATIC FAILURE BY THE BIOLOGIC-DT SYSTEM (1999) (3)
Further experience of late onset hepatic failure. (1993) (2)
Hepatic scintiscanning in fulminant hepatic failure. (1973) (2)
Controlled Hyperventilation in the Management of Cerebral Oedema in Fulminant Hepatic Failure (1985) (2)
High plasma endothelin in hepatorenal syndrome (1991) (2)
Effects of intraportal prostacyclin on hepatic bile flow in the rat. (1986) (2)
The value of scintiscanning in the diagnosis of hepatic tumours using both selenomethionine and technetium. (1970) (2)
Altered Plasma and Platelet Lipids and Their Effect on Platelet Function in Fulminant Hepatic Failure (1984) (2)
BIOLOGIC-DT SYSTEM IN TREATMENT OF ACUTE HEPATIC COMA; RESULTS OF RANDOMIZED, CONTROLLED TRIALS (1996) (2)
Proceedings: Disturbed brain tryptophan metabolism in fulminant hepatic failure. (1975) (1)
Blood Brain Barrier Permeability in Acute Hepatic Failure: Studies in Two Animal Models (1984) (1)
Molecular Adsorbents Recirculating System: Early clinical experience. (2001) (1)
Dimethylarginine (nos inhibitor) levels predict in-patient mortality in alcoholic hepatitis (2005) (1)
Selection of an Adsorbent and Hemoperfusion Column Design (1981) (1)
Inhibition of Rat Brain Na+, K+-ATPase by Serum from Patients with Fulminant Hepatic Failure and the Removal of Inhibitors by Haemoperfusion (1984) (1)
ELEVATED PLASMA CARNITINE CONTENT IN ACUTE (PARACETAMOL-INDUCED) LIVER DAMAGE IN HUMANS (1991) (1)
Proceedings: Fulminant hepatic failure: histological quantitation of surviving liver parenchyma in the evaluation of the cause of death. (1974) (1)
Low myo-inositol and high glutamine levels in the brain are associated with neuropsychological deterioration following induced hyperammonemia (2004) (1)
Pathophysiological basis of clinical changes following treatment with MARS in acute-on-chronic liver failure: A randomized evaluation (2002) (1)
THE ROLE OF DDAH-ADMA IN THE REGULATION OF HEPATIC ENOS ACTIVITY IN ACUTE AND CHRONIC LIVER FAILURE (2008) (1)
Nutrition and the liver and pancreas (1986) (1)
New view on treatment of portal hypertension. (1978) (1)
Intestinal permeability in critical illness and acute liver failure: The relationship with severity of illness, spalanchnic ischemia and survival (1998) (0)
It is justified to biopsy presumed hepatocellular carcinoma (HCC) when the alfa fetoprotein (AFP) is normal. (2001) (0)
P.44 Glycogen degradation during acute liver disease and following orthotopic liver transplantation (1997) (0)
Tumor necrosis factor in tulminant hepatic failure (1990) (0)
Oxygen consumption and mitochondrial function by the brain is severely perturbed during the early phase of liver failure. (2004) (0)
Acute Liver Failure: An Overview (1989) (0)
Fibronectin and liver disease. (1987) (0)
[212] BRAIN SWELLING AND COMA IN CIRRHOTIC RATS ADMINISTERED ENDOTOXIN IS ASSOCIATED WITH INCREASED PROTEIN NITROSATION (2007) (0)
Hepatic inflammation is an important determinant of portal pressure in alcoholic liver disease (2003) (0)
Hepatic Encephalopathy: A multiorgan perspective. (2003) (0)
P.138 Small bowel and colonic permeability in generalICU and acute liver failure patients: association with endotoxaemia (1998) (0)
Gastrointestinal hormonal changes of acute hepatic failure in the pig. (1981) (0)
Endotoxemia and its association with colonic and small bowel permeability in acute liver failure and patients on a general ICU (1998) (0)
O.63 Intestinal permeability in acute liver failure: relationshipwith severity of illness, splanchnic ischaemia and endotoxaemia (1998) (0)
Inhibition of bile secretion in the rat by serum ultrafiltrates and fractions from patients with fulminant hepatic failure. (1988) (0)
In Vivo Reduction of Na+, K+-ATPase Activity in Rat Brain during D-Galactosamine-Induced Acute Hepatic Failure: A Possible Cause of Encephalopathy (1984) (0)
Inflammation significantly exacerbates the effect of hyperammonemia on neurological function in cirrhosis (2003) (0)
Effects of eicosanoids secreted by stimulated Kupffer cells on isolated rat hepatocytes. (1997) (0)
The novel gene nostrin and a splice-variant are highly expressed in alcoholic hepatitis and may explain increased intra-hepatic resistance despite normal eNOS expression (2004) (0)
Is spontaneous bacterial peritonitis, spontaneous? (1991) (0)
PROTHROMBIN TIME AND PARACETAMOL-INDUCED FULMINANT HEPATIC FAILURE (1991) (0)
The cost of variceal bleeding in cirrhosis: A pharmacoeconomic model of the UK variceal haemorrhage guidelines (2003) (0)
Remote ischaemic preconditioning of the hind limb reduces the local and systemic adverse effects of reperfusion injury following total liver ischaemia (2004) (0)
Piroxicam-induced subacute hepatic necrosis. (1986) (0)
Remote ischaemic preconditioning of the hind limb improves systemic haemodynamics and reduces reperfusion injury to the liver and lung (2003) (0)
Selected Commentary to: "Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study" (2005) (0)
Worsening of cerebral hyperaemia in acute liver failure (ALF) with terlipressin (2003) (0)
Encephalopathy Associated with Liver Disease (1989) (0)
Oxidant stress in the pathogenesis of the hepatorenal syndrome (1993) (0)
Treatment with anti-tumour necrosis factor a (TNF alpha) antibody improves clinical parameters and lowers portal pressure in alcoholic hepatitis (2003) (0)
Factor Viii Complex in Fulminant Hepatic Failure (1984) (0)
Experimental Studies of Blood-Brain Barrier Permeability in Chronic Hepatic Encephalopathy (1984) (0)
RECENT ADVANCES IN CLINICAL PRACTICE PROSPECTS FOR EXTRACORPOREAL LIVER SUPPORT (2004) (0)
O.19Intestinal permeability in critical illness: relationshipwith severity of illness, splanchnic ischaemia and endotoxaemia (1998) (0)
Improvement in portal and regional haemodynamics following anti-TNF therapy in alcoholic hepatitis (2003) (0)
Fulminant hepatic failure and artificial liver support. (1985) (0)
Selective digestive decontamination during acute hepatic failure (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With R. W. Williams?

R. W. Williams is affiliated with the following schools:

University College London